Why physiological pacing is changing the future of cardiac resynchronisation therapy
Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction disorders. Yet, as clinical understanding evolves, there is growing recognition that the most effective pacing strategies are those that replicate the heart’s natural electrical conduction as closely as possible.
Increasingly, electrophysiologists are exploring approaches that activate the heart through its intrinsic conduction pathways, rather than relying solely on conventional pacing methods. Known as conduction system pacing, these techniques aim to restore more natural ventricular activation, potentially improving cardiac efficiency and long-term outcomes for patients with complex rhythm disorders. Recent consensus statements from the European Society of Cardiology and collaborating heart rhythm societies only affirm the growing clinical interest in such approaches.
A rise in left bundle area pacing
Among these strategies, left bundle branch area pacing has rapidly gained attention. By targeting the heart’s native conduction network, this approach can produce a more physiological contraction pattern than traditional right ventricular pacing. The European Heart Rhythm Association and collaborating international heart rhythm societies have outlined implantation guidance for conduction system pacing as clinical experience with these techniques continues to rise. For patients with heart failure, atrial fibrillation, or high ventricular pacing requirements, this shift toward more physiologically aligned therapies is beginning to reshape clinical thinking.
The growing interest in conduction system pacing reflects a broader trend in cardiovascular care. Physicians are increasingly treating patients with overlapping conditions, including heart failure, atrial fibrillation, and conduction abnormalities. As populations age and comorbidities become more common, rhythm management strategies must address a level of clinical complexity that was far less common only a decade ago.
Meeting greater complexity in patient needs
This evolving patient landscape is also placing new demands on cardiac device technology. Clinicians are looking for systems that support emerging pacing strategies while maintaining strong arrhythmia detection, therapy delivery, and procedural efficiency.
Recent innovations in implantable cardiac devices are beginning to reflect these changing priorities. One example is the development of high-voltage systems designed to support left bundle branch area pacing alongside established defibrillation and resynchronisation therapies.
Integrating physiological pacing with advanced rhythm management
Pacing within the left bundle branch area can enable more synchronised cardiac contractions. Achieving this physiologic response remains one of the central goals of resynchronisation therapy.
Equally important is the ability to integrate physiological pacing with advanced arrhythmia management. Contemporary devices incorporate features such as enhanced atrial sensing, improved atrial fibrillation detection, and anti-tachycardia pacing strategies designed to reduce arrhythmia burden and the need for shocks.
Adaptive pacing technologies are also emerging. Systems such as Closed Loop Stimulation respond dynamically to changes in cardiac demand, adjusting pacing rates based on real-time physiological signals, rather than relying solely on conventional rate response algorithms.
Workflow considerations are also shaping the next generation of cardiac rhythm devices. With many cardiac patients requiring MRI imaging during their lifetime, automated MRI compatibility has become an increasingly important feature. Technologies that enable safe full body scanning without manual device reprogramming can reduce clinical workload and simplify care pathways for both physicians and patients.
The future of cardiac rhythm management
These developments reflect a broader evolution in cardiac rhythm management. Rather than focusing solely on correcting electrical abnormalities, clinicians are increasingly aiming to restore the heart’s natural electrical behaviour wherever possible.
As conduction system pacing continues to mature, technologies that make these strategies practical in routine clinical care will play an important role in the future of cardiac rhythm management. The next phase of cardiac device innovation will likely be defined not only by therapeutic capability, but also by how effectively these systems support physicians in delivering more physiological and personalised care for increasingly complex patient populations.
References
EHRA clinical consensus statement on conduction system pacing implantation: endorsed by the Asia Pacific Heart Rhythm Society (APHRS), Canadian Heart Rhythm Society (CHRS), and Latin American Heart Rhythm Society (LAHRS) —> https://academic.oup.com/europace/article/25/4/1208/7121146
European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with the special contribution of the European Heart Rhythm Association and endorsement from APHRS, CHRS, HRS, and LAHRS, as an additional reference --> https://academic.oup.com/europace/article/27/4/euaf050/8100402
About the author
Dr David L. Hayes is chief medical officer at BIOTRONIK, where he leads clinical strategy and oversees the development of cardiovascular technologies aimed at improving patient outcomes. A board-certified cardiologist with more than four decades of clinical and academic experience, Dr Hayes has authored more than 300 peer-reviewed publications and over 20 books in the field. He has also held numerous leadership roles, including serving as president of the Heart Rhythm Society and medical director of the Mayo Clinic Care Network.
